In a research note issued today, Maxim Group analyst Jason Kolbert reaffirmed a Buy rating on Agenus Inc. (AGEN) and a price target of $11, after AGEN announced the final data set …
In a research note issued today, Maxim Group analyst Jason Kolbert reiterated coverage with a “Buy” rating on Vertex Pharmaceuticals (VRTX) and increased his price target to $107.00 (from $92.
In a research note issued today, Maxim Group analyst Jason Kolbert reiterated coverage with a “Buy” rating on StemCells Inc. (STEM), and a price target of $2.
In a report published today, Maxim analyst Jason Kolbert reiterated a Buy rating on Inovio Pharmaceuticals, Inc. (INO) with an adjusted price target of $18.
In a research note issued today, Maxim Group analyst Jason Kolbert reiterated a Buy rating and boosted his price target on Achillion Pharmaceuticals (ACHN) to …
In a research note released today, Maxim Group assumed coverage on Advanced Cell Technology, Inc. (ACTC) with a Buy rating and a price …